The CDC intends to award a sole source, firm fixed price contract to CEPHEID for maintenance and support of the proprietary Cepheid GeneXpert DX system, which is used for rapid detection of carbapenemase gene markers. Responses to this notice of intent must be emailed to the contract specialist by 08:00 AM on May 29, 2026. No budget amount is specified. Performance of services will be at the CDC’s location, supporting existing laboratory workflow, surge testing, and wastewater sampling. This is not a request for competitive proposals, but the government will consider all responses received within 15 days.